Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
Cannon
Christopher P
CP
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA cpcannon@partners.org
McCabe
Carolyn H
CH
Belder
Rene
R
Breen
Jeanne
J
Braunwald
Eugene
E
D000789:Angina, Unstable / Q000517:prevention & control; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D023521:Chlamydophila Infections / Q000382:microbiology / Q000517:prevention & control*; D016993:Chlamydophila pneumoniae / Q000187:drug effects*; D008078:Cholesterol, LDL / Q000097:blood*; D004311:Double-Blind Method; D024841:Fluoroquinolones; D000077734:Gatifloxacin; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000382:microbiology / Q000517:prevention & control*; D018410:Pneumonia, Bacterial / Q000382:microbiology / Q000517:prevention & control; D017035:Pravastatin / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
D000890:Anti-Infective Agents; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D024841:Fluoroquinolones; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D017035:Pravastatin; D000077734:Gatifloxacin